ROCKVILLE,
Md., Nov. 8, 2017 /PRNewswire/
-- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for
viral vector production and development, today announced a collaboration with
The Michael J. Fox Foundation for Parkinson's Research (MJFF) for AAV repository
and domestic production. Viral vectors to knockdown mouse or human
alpha-synuclein (aSyn) will be made available for purchase in early 2018.
"We are pleased to have taken
this step to make critical Parkinson's disease research tools more accessible
to the wider research community," stated Dr. Zairen
Sun, Vigene's CEO, "We believe that a key way to accelerate
therapeutic development for Parkinson's patients is to provide validated viral
vectors, that will enable researchers to obtain quality data, so that they
focus on understanding the mechanisms underlying Parkinson's disease."
"The Michael
J. Fox Foundation drives tool development toward the greatest needs of the
field to accelerate therapeutic development in Parkinson's," said Nicole Polinski, PhD, associate director of
research programs at MJFF. "Our partnership with Vigene enables the
distribution of key viral vectors targeting alpha-synuclein — a sticky protein
that clumps in the brains of people with PD — to help deepen understanding of
the mechanisms of Parkinson's and speed urgently needed
breakthroughs."
About Vigene Biosciences
Vigene
Biosciences, Inc is a leader in viral vector based gene delivery for both
life science research, gene therapy and cell therapy purposes. Headquartered in Rockville, Maryland, Vigene offers AAV,
lentivirus and adenovirus based products and custom services. Both research
grade and cGMP grade AAV, lentiviral and adenoviral vectors are
available.
Contact Information
Jeffrey
Hung, Ph.D.
https://www.prnewswire.com/news-releases/vigene-biosciences-partners-with-the-michael-j-fox-foundation-to-distribute-alpha-synuclein-knockdown-viral-vectors-for-parkinsons-disease-research-300552105.htmlChief
Commercial Officer
No comments:
Post a Comment